Liraglutide Protects the Heart From Methotrexate Chemotherapy Damage

Liraglutide ameliorated methotrexate-induced cardiotoxicity in rats through anti-inflammatory and antioxidant pathway modulation, adding chemo-cardioprotection to GLP-1 benefits.

Ali, Dina A et al.·Journal of biochemical and molecular toxicology·2025·Preliminary Evidenceanimal study
RPEP-09863Animal studyPreliminary Evidence2025RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
animal study
Evidence
Preliminary Evidence
Sample
N=small
Participants
Rats receiving methotrexate with or without liraglutide cardioprotection

What This Study Found

Liraglutide ameliorated methotrexate-induced cardiotoxicity in rats through anti-inflammatory and antioxidant pathway modulation, adding chemo-cardioprotection to GLP-1 benefits.

Key Numbers

Four groups of rats tested. Methotrexate given as single dose of 20 mg/kg. Two different liraglutide doses evaluated for cardioprotection.

How They Did This

Study methodology detailed in the full publication.

Why This Research Matters

These findings have practical implications for the growing number of patients using peptide-based therapies.

The Bigger Picture

This study contributes to the expanding evidence for peptide therapeutics in clinical practice.

What This Study Doesn't Tell Us

Study limitations in the full publication.

Questions This Raises

  • ?What are the long-term implications?
  • ?How do results compare to other evidence?
  • ?What further research is needed?

Trust & Context

Key Stat:
Key finding Liraglutide ameliorated methotrexate-induced cardiotoxicity in rats through anti-inflammatory and an
Evidence Grade:
Evidence level based on study design in publication.
Study Age:
Published in 2025.
Original Title:
Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.
Published In:
Journal of biochemical and molecular toxicology, 39(12), e70606 (2025)
Database ID:
RPEP-09863

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / ObservationalSnapshot without intervening
This study
Case Report / Animal Study
What do these levels mean? →

Frequently Asked Questions

What does this mean for patients?

Liraglutide ameliorated methotrexate-induced cardiotoxicity in rats through anti-inflammatory and antioxidant pathway modulation, adding chemo-cardioprotection to GLP-1 benefits.

How reliable is this?

Consult the full publication and healthcare provider.

Read More on RethinkPeptides

Cite This Study

RPEP-09863·https://rethinkpeptides.com/research/RPEP-09863

APA

Ali, Dina A; Ibrahim, Dalia; Kolieb, Eman; Abdel Fattah, Islam O; Maher, Shymaa A; Elkelish, Amr; Abdalneim, Nasir A; Abozied, Nadia. (2025). Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.. Journal of biochemical and molecular toxicology, 39(12), e70606. https://doi.org/10.1002/jbt.70606

MLA

Ali, Dina A, et al. "Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity in Rats: Modulation of Oxidative Stress, Autophagy, and the TNF-α/NF-κB Signaling Inflammatory Pathway.." Journal of biochemical and molecular toxicology, 2025. https://doi.org/10.1002/jbt.70606

RethinkPeptides

RethinkPeptides Research Database. "Liraglutide Ameliorates Methotrexate-Induced Cardiotoxicity ..." RPEP-09863. Retrieved from https://rethinkpeptides.com/research/ali-2025-liraglutide-ameliorates-methotrexateinduced-cardiotoxicity

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkPeptides research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.